Study of a targeted drug for advanced or recurrent ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a drug called IMMU-132, which targets a protein (TROP-2) found on some ovarian cancer cells. It may help people whose cancer has returned or spread and who have not responded well to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have advanced or recurrent ovarian, fallopian tube, or primary peritoneal cancer that is high-grade.
- Your cancer has come back or grown after at least one round of platinum-based chemotherapy, and if it's been less than 6 months since your last chemo, or you've had at least 3 rounds of platinum chemo and can't have more.
- You have a tumor sample that tests positive for TROP-2 with a high score.
- You are generally well enough to be up and about (ECOG score 0-2).
- You have not had a topoisomerase I inhibitor before, and you don't have certain heart, lung, or bleeding conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
This study looks at how well the drug Sacituzumab Govitecan works in real-life settings for people with certain types of advanced breast cancer that have not responded to prior treatments.
This trial is studying how patients with metastatic triple-negative breast cancer feel and function during treatment with sacituzumab govitecan (a targeted therapy) or standard chemotherapy, using patient-reported outcomes. It aims to better understand the real-world effectiveness and impact on quality of life in Chinese patients.
This trial studies IMMU-132 (sacituzumab govitecan) in people whose cervical cancer keeps coming back or stays after prior treatment. It aims to shrink tumors and improve outcomes after at least one chemotherapy has already been tried.
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
This trial tests a drug called sacituzumab govitecan for people with advanced esophageal squamous cell carcinoma that has already been treated with chemotherapy and immunotherapy. The drug targets a protein called Trop-2 on cancer cells to try to stop tumor growth.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.